On page 18, RIC states how its customer mix and other factors provide earnings resilience through earning cycles and mentions 'disease'.
This is the closest it gets to mention of the topic that in recent weeks sometimes has been garnering media's attention: foot and mouth disease.
Being alarmist is ill-advised, but if FMD gets in and spreads, one assumes it would be of major detriment to RIC and its competitors.
On page 18, RIC states how its customer mix and other factors...
Add RIC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.55 |
Change
-0.010(0.39%) |
Mkt cap ! $805.3M | |||
| Open | High | Low | Value | Volume |
| $2.59 | $2.59 | $2.52 | $430.9K | 168.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2470 | $2.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.57 | 2470 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| RIC (ASX) Chart |